Biosig Technologies, INC 8-K filings

BioSig Technologies has regained compliance with Nasdaq's minimum bid price requirement after its common stock price remained above $1.00 for ten consecutive business days.

BioSig Technologies plans to merge with Streamex Exchange Corporation in an all-stock transaction, pivoting towards real-world asset tokenization.

BioSig Technologies announces a change in its independent registered public accounting firm, with Marcum LLP resigning and CBIZ CPAs P.C. being engaged, effective April 30, 2025.

BioSig Technologies issued 2.75 million restricted shares of common stock to service providers on April 24, 2025, in exchange for business development services.

BioSig Technologies received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

BioSig Technologies has been notified by Nasdaq that it has regained full compliance for continued listing on the Nasdaq Capital Market after demonstrating compliance with the Equity Rule.

BioSig Technologies believes it has met Nasdaq's minimum stockholders' equity requirement of $2.5 million following recent stock sales and an equity subscription agreement.

BioSig Technologies entered into a Securities Purchase Agreement to sell shares and warrants for an aggregate consideration of $818,997.91.

BioSig Technologies secures a $5 million equity line with Lind Global Fund III, LP, providing the company with the option to sell shares over the next 36 months.

BioSig Technologies' stockholders approved an increase in shares for the incentive plan and a reverse stock split at their annual meeting on December 31, 2024.

BioSig Technologies has entered into an agreement to sell up to $8.5 million of its common stock through an at-the-market offering.

BioSig Technologies successfully had a lawsuit dismissed that was filed by a former employee regarding a restricted stock award agreement.

BioSig Technologies has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive days.

BioSig Technologies has received a notification from Nasdaq stating that it does not meet the minimum bid price requirement of $1.00 per share.

BioSig Technologies has been granted an extension until March 7, 2025, to meet Nasdaq's minimum market value requirement and will resume trading on October 23, 2024.

BioSig Technologies has appointed its CEO, Anthony Amato, as Chairman of the Board and entered into a new executive employment agreement with him, effective August 1, 2024.

BioSig Technologies began trading on the OTCQB market on July 23, 2024, following its delisting from the Nasdaq.

BioSig Technologies' appeal to reconsider its delisting from Nasdaq was declined, and the company is now seeking to trade on the OTC Markets OTCQB platform while pursuing a further appeal.

BioSig Technologies will be delisted from the Nasdaq due to non-compliance with minimum stockholders' equity requirements, with trading to move to the OTC Markets Pink tier.

BioSig Technologies has appointed Ferdinand Groenewald as interim CFO and principal accounting officer, effective June 5, 2024, following the resignation of Frederick D. Hrkac.

BioSig Technologies has successfully raised $3 million through a registered direct offering and concurrent private placement, issuing shares and warrants to institutional investors.

BioSig Technologies has been granted a Nasdaq listing extension, contingent on meeting a $2.5 million stockholders' equity requirement by June 6, 2024.

BioSig Technologies has appointed its independent directors to the Audit, Compensation, and Nominating and Corporate Governance Committees, effective May 20, 2024.

BioSig Technologies has regained compliance with Nasdaq's minimum bid price requirement, but still faces potential delisting due to other non-compliance issues.

BioSig Technologies has entered into a securities purchase agreement, issuing common stock and warrants to accredited investors for a total consideration of $1,144,164.46.

BioSig Technologies has appointed three new independent directors, Steven E. Abelman, Donald F. Browne, and Chris Baer, to its board, completing its composition.

BioSig Technologies has appointed Anthony Amato as its new CEO and director, effective immediately, as part of a comprehensive turnaround strategy.

BioSig Technologies has appointed Chris Baer, a seasoned medical device executive, to its board of directors, effective May 2, 2024.

BioSig Technologies is facing potential delisting from the Nasdaq Capital Market due to failure to meet minimum bid price and market capitalization requirements, compounded by significant operational and governance issues.

BioSig Technologies has issued a $500,000 promissory note with a 12% interest rate, due in 2026, to an investor.